 CytoSorbents Corporation Nasdaq: CTSO, a critical care immunotherapy leader commercializing its CytoSorb blood purification technology to treat cytokine storm and deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that the Data Monitoring Committee DMC of the REFRESH 2-AKI trial has completed a comprehensive favorable review of safety data from the study with a positive recommendation to resume the trial. 